Zimmer Biomet Holdings Stock Price and Value Analysis

Zimmer Biomet Holdings (NYSE:ZBH) in our automated value investing analysis, with the cash flow history and price comparison below.

Key Facts

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold Zimmer Biomet Holdings to reach your target.

Target type

ZBH Free Cash Flow Trend

Free Cash Flow trendline for ZBH
Free Cash Flow trendline for Zimmer Biomet Holdings
CSV

Based on historical returns, we believe that Zimmer Biomet Holdings can grow its free cash at a rate of about 6%. That's positive!

AdvantagesDisadvantages
  • This company is making money at a decent rate.
  • This company has stable growth.
  • This company is less known than others.
  • This stock looks overpriced.
  • This company has a low dividend yield.

Inside the ZBH Numbers

ZBH Price
(Zimmer Biomet Holdings stock price per share)
$101.10
[?] ZBH Fair Price
(based on intrinsic value)
$67.09
[?] ZBH Safety Price (based on a variable margin of safety) $40.25
Try your own return

The fair price above uses a 10.1% discount rate, the long-run US stock return (10.1% geometric, 1926 to 2025, from Bessembinder's working paper, updated 2026-11-09), and 2.5% terminal growth. A higher rate suits a higher return target and gives a lower value.

Value per share:

[?] PE Ratio versus Sector 25% higher than other Healthcare stocks
[?] PE Ratio versus Industry 5% higher than other Medical Instruments & Supplies stocks
[?] Free Cash Flow Jitter 16%
[?] Dividend Yield 0.95% (tax impact)
Shares Shorted 7,848,223

Insider Activity Summary

No open-market insider buys or sells are recorded for the last 12 months.

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 7,848,223 shares shorted. With 188,650,168 shares available for purchase and an average trading volume over the past 10 trading days of 2,318,830, it would take at least 3.4 days for all of the short holders to cover their shorts.

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Free Cash Flow by Fiscal Year

How to read this: free cash flow in plain terms, free cash flow jitter.

Each year names the SEC filer that reported it, so a change of filer shows up here.

Fiscal yearSEC filer (CIK)Free cash flow (USD millions)
2007 1136869 892
2008 1136869 817
2009 1136869 935
2010 1136869 1,037
2011 1136869 1,029
2012 1136869 1,019
2013 1136869 861
2014 1136869 950
2015 1136869 722
2016 1136869 1,490
2017 1136869 1,432
2018 1136869 1,584
2019 1136869 1,410
2020 1136869 1,040
2021 1136869 1,343
2022 1136869 1,194
2023 1136869 1,393
2024 1136869 1,312
2025 1136869 1,487

Download the yearly data as CSV.

Cash Conversion

How to read this: what free cash flow is, why earnings matter.

Over the 17 fiscal years from 2007 to 2025 with positive net income, operating cash flow totaled $22,070 million against net income of $12,617 million, or 1.75 times. Net income was negative in 2 of the 19 years, and those years are left out of the ratio.

In 2025, operating cash flow was 2.41 times net income, compared with 1.39 times for the earliest three years (2007 to 2009).

In 2025, capital expenditures were $225 million, 13.2% of operating cash flow of $1,697 million, which leaves an estimated $1,473 million after capex. Across the 19 years with reported capex, it averaged 12.6% of operating cash flow. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.

Fiscal yearNet income (USD millions)Operating cash flow (USD millions)Capital expenditures (USD millions)Operating cash flow / net income
2007 773 1,084 193 1.40
2008 849 1,038 250 1.22
2009 717 1,118 105 1.56
2010 597 1,194 79.2 2.00
2011 761 1,177 114 1.55
2012 755 1,152 115 1.53
2013 780 963 100 1.23
2014 720 1,061 145 1.47
2015 147 850 168 5.78
2016 306 1,632 185 5.34
2017 1,814 1,582 156 0.87
2018 -379 1,747 163 n/a
2019 1,132 1,586 207 1.40
2020 -139 1,205 112 n/a
2021 402 1,499 144 3.73
2022 231 1,356 188 5.86
2023 1,024 1,582 291 1.54
2024 904 1,499 204 1.66
2025 705 1,697 225 2.41

Where the Cash Went

How to read this: why companies buy back shares, dividend yield explained.

Over the 10 fiscal years from 2016 to 2025 with dividend or share repurchase facts, estimated free cash flow totaled $13,684 million. That estimate uses the average of up to five years of capital expenditures, not each year's own, so it is not a reported figure.

In the 10 of those years with dividend payment facts, dividends paid totaled $1,961 million, 14.3% of the estimated free cash flow of those years. Estimated free cash flow was at least the dividends paid in 10 of those 10 years.

In 5 of the 10 years, cash spent repurchasing shares was at least 5% of that year's estimated free cash flow, and in those years it totaled $2,589 million. Smaller amounts are left out of this sentence because they can be shares withheld to pay employees' taxes on stock awards.

In 2025, dividends and cash spent repurchasing shares together were $677 million, 45.6% of estimated free cash flow of $1,487 million.

Fiscal yearEstimated free cash flow (USD millions)Dividends paid (USD millions)Cash spent repurchasing shares (USD millions)Total returned (USD millions)Total as a percent of estimated free cash flow
2016 1,490 188 416 604 40.5%
2017 1,432 194 n/a 194 13.5%
2018 1,584 195 n/a 195 12.3%
2019 1,410 197 n/a 197 13.9%
2020 1,040 199 n/a 199 19.1%
2021 1,343 200 n/a 200 14.9%
2022 1,194 201 126 328 27.4%
2023 1,393 201 692 893 64.1%
2024 1,312 196 868 1,064 81.1%
2025 1,487 190 487 677 45.6%

Free cash flow here is an estimate: operating cash flow less the average of up to five years of capital expenditures. Cash spent repurchasing shares can include shares withheld to pay employees' taxes on stock awards. The entry n/a means the filings gave no usable figure, not that the amount was zero. Source: the company's annual reports to the SEC.

Revenue and Cash Margin

How to read this: earnings and margins.

Revenue was $3,898 million in 2007 and $8,232 million in 2025, a compound annual growth rate of 4.2% over 18 years.

Revenue rose 7.2% from 2024 to 2025.

Our estimated free cash flow was $1,487 million in 2025, 18.1% of revenue. In 2007 the estimated margin was 22.9%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.

Fiscal yearRevenue (USD millions)Estimated free cash flow (USD millions)Estimated free cash flow / revenue
2007 3,898 892 22.9%
2008 4,121 817 19.8%
2009 4,095 935 22.8%
2010 4,220 1,037 24.6%
2016 7,668 1,490 19.4%
2017 7,803 1,432 18.3%
2018 7,933 1,584 20.0%
2019 7,982 1,410 17.7%
2020 6,128 1,040 17.0%
2021 6,827 1,343 19.7%
2022 6,940 1,194 17.2%
2023 7,394 1,393 18.8%
2024 7,679 1,312 17.1%
2025 8,232 1,487 18.1%

Balance Sheet

How to read this: how debt and assets are compared, the current ratio.

In 2025, cash and equivalents were $592 million against total liabilities of $10,386 million, or 5.7% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.

Total liabilities were 45.0% of total assets in 2025, compared with 21.9% in 2008, an increase of 23.1 percentage points.

Stockholders equity was $12,706 million in 2025, compared with $5,654 million in 2008, a rise of 124.7%.

Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was 7.5% in 2025. Invested capital here is total assets less cash and current liabilities.

Fiscal yearTotal assets (USD millions)Cash and equivalents (USD millions)Total liabilities (USD millions)Stockholders equity (USD millions)
2008 7,239 213 1,585 5,654
2009 7,786 692 2,147 5,639
2010 8,000 669 2,229 5,771
2011 8,515 768 3,001 5,515
2012 9,012 884 3,164 5,866
2013 9,595 1,081 3,270 6,300
2014 9,658 1,083 3,106 6,552
2015 27,161 1,459 17,271 9,889
2016 26,684 634 17,015 9,670
2017 26,014 524 14,279 11,736
2018 24,127 543 12,851 11,276
2019 24,639 618 12,246 12,393
2020 24,418 802 12,218 12,199
2021 23,456 378 10,790 12,666
2022 21,066 376 9,039 12,027
2023 21,497 416 9,009 12,488
2024 21,365 526 8,889 12,476
2025 23,092 592 10,386 12,706

Price Versus Our Estimated Value

Zimmer Biomet Holdings is priced at $101.10, above our fair value estimate of $67.09 and its safe value of $40.25.

Free cash flow was positive in all 19 fiscal years we have for Zimmer Biomet Holdings under its current SEC filer.

Free cash flow from the first three years of data averaged $881 million, and from the last three $1,397 million: a sharp rise.

Free cash flow is fairly steady from year to year, with a variability measure of 16%.

Before you act on any of this, read what a margin of safety means and check the company's own filings.

The dividend yield for Zimmer Biomet Holdings is 0.95%.

Compared With Its Sector and Industry

How to read this: the price to earnings ratio.

Its trailing P/E ratio is 25% above the average for stocks in the Healthcare sector.

Its trailing P/E ratio is 5% above the average for stocks in the Medical Instruments & Supplies industry.

A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.

Closest Industry Peers

These are companies in the Medical Instruments & Supplies industry, the ones closest in market capitalization to Zimmer Biomet Holdings, limited to companies whose pages we publish. The figures come from our latest data for each company.

CompanyMarket cap (USD millions)P/EDividend yieldCash yieldPrice versus our estimate
Zimmer Biomet Holdings (ZBH) 19,134 25.5 0.9% - 51% above
The Cooper Companies (COO) 11,196 20.2 - 3.0% 17% below
MSA Safety Incorporated (MSA) 6,550 21.8 1.2% 0.8% 277% above
DENTSPLY SIRONA (XRAY) 1,653 - 1.9% 33.8% 84% below
Alpha Pro Tech, Ltd. (APT) 61.2 12.2 - - 2% below
Edwards Lifesciences Corporation (EW) 58,564 59.2 - 0.9% 148% above
Intuitive Surgical (ISRG) 138,328 48.3 - 0.6% 244% above

Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.

Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.

SEC Filer History

Every fiscal year on this page is reported by one SEC filer, CIK 1136869.

Each figure on this page comes from that filer.

Risks to This Analysis

How to read this: understanding investment risk.

  • These figures are automated calculations from SEC filings and the recent price. They may contain errors, and they do not reflect lawsuits, management changes, or other events the filings do not show.

How This Page Is Made

Latest annual report used
Fiscal year 2025
Price and market data last refreshed
2026-11-20
Model assumptions last reviewed
2026-11-09

Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.

Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.

The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.

This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.

Read the filings yourself: ZBH annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.

Advertisement supports free stock analysis content.

Questions to Answer Before You Invest in ZBH

Does Zimmer Biomet Holdings have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Worked example: ZBH

This example shows how we apply the Trendshare checklist to ZBH: earnings power, cash generation, valuation, and margin of safety.

We check: business quality, free cash flow, P/E, and margin of safety.

  1. Step 1 — Snapshot

    • Price: 101.10
    • Market cap: $19B
    • EPS: 3.96
  2. Step 2 — Valuation checks

    • P/E: 25.53
    • FCF yield: —
    • Date checked: Nov 20, 2026
  3. Step 3 — Margin of safety

    • Compare price to fair value and safety price.
    • Look for durable cash generation and reasonable leverage.
    • Decide if it passes your personal checklist.